Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome

Circulation Journal

Volumn 72, Issue 10, 2008, Pages 1605-1609

  Wu, Tong Guo ^a,c   Zhao, Qiang ^a   Huang, Wei Guang ^a   Wei, Jian Rui ^a   Chen, Si Wei ^a   Zhao, Jin ^a   Huang, Li Ping ^a   Wang, Le Xin ^b  

^a JINAN UNIVERSITY   (China)

^b CHARLES STURT UNIVERSITY   (Australia)

^c GUANGZHOU RED CROSS HOSPITAL   (China)

Author keywords

Acute coronary syndrome; Percutaneous coronary intervention; Tirofiban

Indexed keywords

TIROFIBAN;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY VESSELS; DRUG ADMINISTRATION ROUTES; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY; TYROSINE;

EID: 52749095514     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0357     Document Type: Article

References (19)

1. Acute Coronary Syndrome Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006; 184: S1-S32.
2. King SB III, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295.
3. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1886-1889.
4. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Sub-optimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002; 89: 647-650.
5. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91: 334-336.
6. Valgimigli M, Percolo G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty (the ADVANCE trial). J Am Coll Cardiol 2004; 44: 14-19.
7. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions. J Am Coll Cardiol 2006; 47: 522-528.
8. Wöhrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003; 107: 1840-1843.
9. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007; 23: 57-63.
10. Heer T, Zeymer U, Juenger C, Gitt AK, Wienbergen H, Zahn R, et al; Acute Coronary Syndromes Registry Investigators. Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice. Heart 2006; 92: 1484-1489.
11. Tan K, Sulke N, Taub N, Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: Current experience. J Am Coll Cardiol 1995; 25: 855-865.
12. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312: 932-936.
13. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-130.
14. Kalaria VG, Rouch C, Bourdillon PD, Breall JA. Distal emboli protection in patients undergoing percutaneous coronary intervention after a recent myocardial infarction. Catheter Cardiovasc Interv 2002; 57: 54-60.
15. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96: 1445-1453.
16. Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis). J Am Coll Cardiol 1998; 32: 28-34.
17. Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: The TARGET Trial. Circulation 2002; 105: 2347-2354.
18. Chen SM, Hsieh YK, Guo GB, Fang CY, Yip HK, Wu CJ, et al. Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention. Circ J 2006; 70: 536-541.
19. Yip HK, Youssef AA, Chang LT, Yang CH, Sheu JJ, Chua S, et al. Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Circ J 2007; 71: 1086-1091.